Henry Schein (HSIC) is Reiterated by Barrington Research to Outperform, Raises Price Target to $ 188

Henry Schein (HSIC) was Reiterated by Barrington Research to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 188 from a previous price target of $182 . Barrington Research advised their investors in a research report released on May 4, 2016.

Many Wall Street Analysts have commented on Henry Schein. Henry Schein was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Barrington Research Upgraded Henry Schein on Mar 1, 2016 to ” Outperform”, Price Target of the shares are set at $182.Company shares were Reiterated by Piper Jaffray on Feb 11, 2016 to “Neutral”, Firm has raised the Price Target to $ 159 from a previous price target of $158 .

On the company’s financial health, Henry Schein reported $1.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $1.39. The company had revenue of $2712.96 million for the quarter, compared to analysts expectations of $2667.28 million. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.

Henry Schein opened for trading at $168.86 and hit $171.21 on the upside on Monday, eventually ending the session at $171, with a gain of 1.36% or 2.3 points. The heightened volatility saw the trading volume jump to 5,84,507 shares. Company has a market cap of $14,012 M.

In a different news, on Mar 16, 2016, Lonnie Shoff (CEO, Global Strat Port Grp) sold 3,028 shares at $168.29 per share price. According to the SEC, on Mar 15, 2016, David Mckinley (President, Medical Group) sold 3,339 shares at $167.92 per share price. On Mar 15, 2016, Norman S Matthews (director) sold 5,335 shares at $167.76 per share price, according to the Form-4 filing with the securities and exchange commission.

Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.

Henry Schein

Leave a Reply

Henry Schein - Is it time to Sell?

Top Brokerage Firms are advising their investors on Henry Schein. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.